ArticleFrontiers in genetics2026
Integrated multi-omics analysis identifies candidate eRNA-associated signatures shared between osteoarthritis and type 2 diabetes.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) and type 2 diabetes mellitus (T2DM) frequently coexist and share inflammatory and metabolic disturbances, but the immune-epigenetic features that may overlap between these conditions remain incompletely defined. Enhancer RNAs (eRNAs) are increasingly recognized as regulators of enhancer activity and transcriptional programs, whereas eRNA-associated signatures shared between OA-related and T2DM-related datasets remain largely unexplored. Methods: Transcriptomic datasets from OA joint tissues and controls (63 OA, 35 controls) were analyzed together with an independent T2DM dataset of CD14 Results: We identified 473 annotated dysregulated eRNA-associated features in OA, with associated genes enriched in skeletal development, extracellular matrix remodeling, and PI3K-Akt signaling. CIBERSORT-based and pathway analyses suggested immune-associated transcriptional alterations and inflammatory pathway activation in OA. Integrative analysis prioritized TOB1 as a candidate eRNA-associated feature related to JUN, Conclusion: TOB1 was prioritized as a candidate eRNA-associated signal related to JUN,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.